Investor Relations Overview

NeoGenomics, Inc. is a high-complexity CLIA—certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry.  The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing.  Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA, Tampa, FL and Fort Myers, FL.  NeoGenomics services the needs of pathologists, oncologists, other clinicians and hospitals throughout the United States. For additional information about NeoGenomics, visit neogenomics.com.  

NeoGenomics (NASDAQ: NEO) 4:00 PM ET on Aug 26, 2016
Last Price Change Open Day High 52-Week High
8.07
0.15  up   (1.894%) 7.90 8.11 9.54
Volume Previous Close Day Low 52-Week Low
268,227 7.92 7.80 5.49

 
Stock price graph

The stock information provided is for informational purposes only and is not intended for trading purposes. The stock information is provided by eSignal, stock charts are provided by EDGAR Online, both third party services, and NeoGenomics does not maintain or provide information directly to this service. Stock information is delayed approximately 20 minutes.

Company Overview Presentation

Download our Company Overview

Second Quarter 2016 Earnings Release

View all »   RSSFinancial News

Jul 26, 2016
NeoGenomics Reports 159% Revenue Growth to $63.1 Million and Strong Gains in Profitability in the Second Quarter of 2016

Jul 5, 2016
NeoGenomics Schedules its Q2 2016 Earnings Release for July 26, 2016

Apr 27, 2016
NeoGenomics Reports 159% Revenue growth to $59.7 Million and 442% Adjusted EBITDA increase to $8.2 Million, Driven by Clarient acquisition and Strong Volume Gains